Yuviwel is a prodrug of C-type natriuretic peptide (CNP). That means it slowly releases CNP in your child’s body over the week to keep levels steady between doses. The released CNP helps counter too much signaling from fibroblast growth factor receptor 3 (FGFR3), which is a key driver in achondroplasia. By rebalancing this signal, it supports bone growth.
Achondroplasia is a rare genetic condition that affects body structure and growth. It is estimated to affect more than 250,000 people around the world. People living with achondroplasia can have bone differences and a higher chance of muscle, nerve, or heart-lung problems.
This approval changes how care can look day to day. This medicine is the only option that uses a once-weekly schedule for eligible children with achondroplasia, and it is designed to provide steady CNP exposure during the week.
In simple terms, Yuviwel aims to dial down the overactive FGFR3 pathway. CNP blocks a growth signal known as the mitogen-activated protein kinase (MAPK) pathway. This action helps cartilage cells in growth plates mature and multiply, which can support longer bones over time.
Why Was It Approved?
Yuviwel received an accelerated approval. The decision was based on an improvement in annualized growth velocity (AGV), which measures how fast a child grows over a year. Continued approval may depend on follow-up studies that confirm real-world benefit.
In a study lasting one year, children who received this medicine grew faster than those who received a placebo. On average, children on Yuviwel gained about 1.5 more centimeters (a little more than half an inch) of height per year and also showed better scores on an achondroplasia-specific growth measure. These results suggest a meaningful increase in growth rate over a year.
Side effects seen in studies included vomiting, reactions where the needle went in, pain in the arms or legs, and nausea. A key safety concern is low blood pressure. Call your health care provider right away if you notice dizziness, unusual tiredness, or nausea, which can be warning signs.
The main study enrolled children about 2 to 12 years old. People with serious heart and blood vessel disease were not included. Use in children younger than 2 years has not been established. Because the approval is accelerated, more research is planned to verify and describe clinical benefit.
What Do I Need to Know?
Yuviwel is given once a week as a shot under the skin. The dose is based on body weight. Your health care provider will track growth and adjust the dose as needed. Treatment stops when growth plates have closed. You can inject in the belly, away from the belly button, or the thigh. If a caregiver gives the shot, the buttocks or the back of the upper arm can also be used. Rotate the site each week and avoid areas that are red, swollen, or scarred.
If you miss a dose, you can take it up to two days before or two days after the usual day, and then return to your regular weekly schedule. Make sure there is enough time between doses as directed by your health care provider. This medicine can lower blood pressure. Contact your health care provider right away if you feel dizzy, very tired, or nauseated. Ask about kidney health before starting. Yuviwel is not recommended if your child has moderate or severe kidney problems.
The company expects the medicine to be available in the U.S. in the early part of the second quarter of 2026. The company also plans support services to help you start and stay on treatment, including possible financial help if you qualify. Ask your health care provider how Yuviwel fits your child’s care plan. Review the expected benefits, possible side effects, and what monitoring is needed. Bring a list of all medicines, vitamins, and supplements to discuss potential concerns.
